This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) ~~Use of the compounds of the following formula (I)~~ A method for the treatment of postlesional diseases of ischemic, traumatic or toxic origin, comprising administering an effective amount of a compound of formula (I):



wherein X represents OH, (C_{1-5})alkoxy, NH_2, NH-C_{1-5}-alkyl, or N(C_{1-5} alkyl)$_2$;

R_1 is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a (C_{1-5}) alkoxy group, a (C_{1-5}) alkyl group or a halogen atom, and Ala, Val, Leu, or Ile;

R_2 is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu ~~and~~ or Asn;

R_3 and R_4 independently represent H, OH, (C_1-C_5)alkyl, or (C_{1-5})alkoxy, provided that R_3 and R_4 are not both OH or (C_{1-5})alkoxy;

R_5 represents H, OH, (C_{1-5}) alkyl or (C_{1-5})alkoxy;

and wherein R_0 represents a group of the formula



wherein Y represents -CO-, -CH_2CO-, -CH_2CH_2CO-, -$CH_2CH_2CH_2$CO-, -CH=CH-CO or -OCH_2CO-, and wherein Z represents a halogen atom, a trifluormethyl group, (C_{1-4}) alkoxy group, (C_{1-4}) alkyl group; or wherein two neighboring substituents may form a (C_{1-3}) alkylendioxy group; and wherein n is 0 or an integer of from 1 to 5;
or pharmaceutically acceptable salts thereof~~;~~ .
~~for the preparation of a medicament useful in the treatment of postlesional diseases of ischemic, traumatic or toxic origin.~~

2. (currently amended) The ~~use~~ method according to claim 1, wherein R_1 is a residue derived from any of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted by a (C_{1-5}) alkoxy group, a (C_{1-5}) alkyl group or a halogen atom, or a residue derived from the amino acid Ile.

3. (currently amended) The ~~use~~ method according to claim 2, wherein R_1 is a residue derived from Phe which may optionally be substituted by a (C_{1-5}) alkoxy group, a (C_{1-5}) alkyl group or a halogen atom.

4. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein X is (C_{1-5}) alkoxy, NH_2, NH-C_{1-5} alkyl, or N(C_{1-5} alkyl)$_2$.

5. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein R_2 is a residue derived from the amino acid Gly or Ile.

6. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein R_0 is a cinnamoyl moiety.

7. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein the compound of formula (I) is cinnamoyl-glycyl-Lphenylalanyl-L-prolinamide, cinnamoyl-isoleucyl-phenylalanyl-L-proline ethylamide, cinnamoyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.